Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Keyphrases
Amphotericin B
13%
Antibiotics
8%
Antifungal Activity
30%
Antifungal Effect
12%
Antifungal Resistance
37%
Antifungal Susceptibility
59%
Antimicrobial Peptides
53%
At-risk
12%
Aurès
91%
Autoimmune Hemolytic Anemia
24%
Balb C Mice
12%
Biofilm Cells
6%
Bogota Colombia
28%
Broth Microdilution
15%
C.albicans
37%
C.glabrata
30%
C.tropicalis
22%
Candida Albicans (C. albicans)
90%
Candida Auris
60%
Candida Dubliniensis
12%
Candida Glabrata
17%
Candida Guilliermondii
12%
Candida Infection
12%
Candida Isolates
9%
Candida Parapsilosis
12%
Candida Species
61%
Candida Tropicalis
12%
Candidiasis
12%
Caspofungin
9%
Cell Surface
16%
Cell Viability
30%
Clinical Impact
12%
Clinical Profile
24%
Clonal Dispersal
12%
Co-infection
24%
Colombia
74%
Colombians
16%
Comorbidity Treatment
8%
Critically Ill Patients
8%
Disseminated Candidiasis
24%
Emerging Threats
12%
Epidemiological Data
17%
Epidemiological Profile
24%
Epidemiology
52%
Fluconazole
38%
Flucytosine
9%
Fungal Burden
24%
Fungemia
8%
Genetic Diversity
48%
Healthcare Settings
12%
High Mortality
9%
Histological Analysis
12%
Immunocompromised Patients
10%
Immunosuppressive Therapy
9%
In Vitro Antifungal Activity
24%
Indigenous Peoples
9%
Indigenous Women
24%
Intracellular Level
6%
Invasive Aspergillosis
28%
Invasive Candidiasis
57%
Invasive Fungal Infection
12%
Invasive Infection
17%
Kidney
12%
L929
6%
Latin America (LATAM)
24%
Local Surveillance
8%
Medical Importance
24%
Morphological Changes
22%
Mortality Rate
14%
Multidrug-resistant
22%
Multidrug-resistant Microorganisms
16%
Multiple Pathogens
24%
Murine Fibroblasts
6%
Murine Model
24%
Non-albicans
9%
Opportunistic Yeasts
8%
Overall Mortality
8%
Parapsilosis
17%
Peptide Toxicity
12%
Pharmacological Resistance
6%
Planktonic Cells
6%
Pore-forming Peptide
24%
Potential Therapeutics
6%
Public Health Risk
10%
Rare Yeasts
24%
Resistant Isolate
12%
Resistant Strains
9%
Ribosomal DNA
12%
Scanning Electron Microscopy
16%
Synthetic Mimics of Antimicrobial Peptides (SMAMPs)
6%
Synthetic Peptides
36%
Therapeutic Potential
24%
Therapeutic Use
24%
Trichosporon Asahii
8%
Tuberculosis
24%
Type 1 Diabetes Mellitus (T1DM)
8%
Vero Cells
24%
Voriconazole
8%
XTT Assay
6%
Yeast Cells
16%
Immunology and Microbiology
Antifungal Activity
48%
Antifungal Resistance
53%
Antifungal Susceptibility
56%
Antimicrobial Peptides
51%
Aspergillus
24%
Aspergillus fumigatus
24%
Bagg Albino Mouse
12%
baker's yeast
24%
Biofilm
11%
Broth Dilution
13%
Candida
100%
Candida albicans
62%
Candida Auris
70%
Candida Dubliniensis
10%
Candida glabrata
10%
Candida parapsilosis
10%
Candida tropicalis
10%
Cell Surface
15%
Cell Viability
28%
Comorbidity
6%
Computer Assisted Tomography
24%
Epidemiological Data
15%
Genetic Variability
48%
Immunocompromised Patient
24%
Isoprenaline
24%
Meyerozyma guilliermondii
10%
Microorganism
12%
Minimum Inhibitory Concentration
6%
Morphology
20%
Mortality Rate
33%
Peptides
72%
Rhodotorula
24%
Rhodotorula mucilaginosa
24%
Scanning Electron Microscopy
15%
Sputum
24%
Trichosporon
24%
Trichosporon asahii
24%
Yeast Cell
15%
Pharmacology, Toxicology and Pharmaceutical Science
Amphotericin B
8%
Antibiotics
8%
Antifungal Activity
24%
Antifungal Agent
8%
Candida
72%
Candida albicans
20%
Candida Auris
40%
Candida Dubliniensis
16%
Candida glabrata
16%
Candida parapsilosis
16%
Candida tropicalis
16%
Candidiasis
25%
Caspofungin
16%
Comorbidity
8%
Diabetes Mellitus
8%
Echinocandin
8%
Fluconazole
24%
Flucytosine
16%
Infection
32%
Invasive Candidiasis
48%
Meyerozyma guilliermondii
16%
Mortality Rate
12%
Mould
8%
Polypeptide Antibiotic Agent
24%
Pyrrole Derivative
8%
Resistance to Antifungal Agent
24%
Ribosome DNA
16%
Synthetic Peptide
24%
Voriconazole
8%